Program Year 2021
General Payments771,324 providers 1,723 companies
Dataset totals — PY2021
$2,283,218,269.44
- Category: General Payments
- Program year: 2021
- Records: 11,517,063
- Providers: 771,324
- Reporting companies: 1,723
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- Dataset-level totals for the labeled program year, General Payments only. Research and Ownership/Investment are separate datasets and are never combined into these figures.
- Methodology & Data — sourcing, labeling, and limitations.
Coverage: program years 2018–2024 are loaded, General Payments only. This page reflects the CMS publication snapshot for PY2021.
Reported totals by company — PY2021 (20 shown)
Sorted by reported total — a dataset fact, not a ranking of conduct.
| Company | Reported | Records | Providers |
|---|---|---|---|
| Medtronic, Inc. | $136,084,588.75 | 208,134 | 55,176 |
| Hill-Rom, Inc | $110,558,486.75 | 2 | 1 |
| Stryker Corporation | $108,143,220.37 | 109,353 | 23,384 |
| ABBVIE INC. | $92,107,722.82 | 1,332,923 | 167,238 |
| Arthrex, Inc. | $88,164,628.42 | 36,537 | 3,448 |
| Zimmer Biomet Holdings, Inc. | $87,857,883.20 | 69,326 | 18,320 |
| DePuy Synthes Products LLC | $69,739,902.56 | 2,161 | 364 |
| Allergan Inc. | $64,305,291.47 | 191,851 | 43,040 |
| Henry Schein, Inc. | $44,717,730.90 | 1,268 | 922 |
| INTUITIVE SURGICAL, INC. | $42,224,242.31 | 64,590 | 9,634 |
| Acerta Pharma LLC | $40,722,677.03 | 435,787 | 104,750 |
| VERTEX PHARMACEUTICALS INCORPORATED | $39,688,019.05 | 958 | 434 |
| BOSTON SCIENTIFIC CORPORATION | $37,285,503.07 | 148,708 | 46,330 |
| PFIZER INC. | $36,532,016.38 | 308,711 | 98,758 |
| Smith & Nephew, Inc. | $28,640,700.84 | 59,063 | 17,712 |
| Novo Nordisk AS | $27,287,330.99 | 473,303 | 80,150 |
| Merck Sharp & Dohme Corporation | $26,804,967.61 | 213,289 | 88,594 |
| Amgen Inc. | $24,930,803.36 | 364,239 | 87,264 |
| GlaxoSmithKline, LLC. | $23,949,992.19 | 307,801 | 72,111 |
| Abbott Laboratories | $23,283,686.31 | 233,075 | 56,126 |
Reported totals by specialty — PY2021 (20 shown)
Sorted by reported total.
Other program years
Natures of payment
- Royalty or License
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
- Consulting Fee
- Food and Beverage
- Acquisitions
- Travel and Lodging
- Education
- Honoraria
- Current or prospective ownership or investment interest
- Grant
- Compensation for serving as faculty or as a speaker for a medical education program
- Gift
- Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program
- Debt forgiveness
- Long term medical supply or device loan
- Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program
- Charitable Contribution
- Entertainment